Methotrexate for the Treatment of Crohn's Disease

New England Journal of Medicine

Volumn 332, Issue 5, 1995, Pages 292-297

  Feagan, Brian G ^a   Rochon, James ^a   Fedorak, Richard N ^a   Irvine, E Jan ^b   Wild, Gary ^c   Sutherland, Lloyd ^d   Steinhart, A Hillary ^e   Greenberg, Gordon R ^e   Gillies, Richard ^f   Hopkins, Marybeth ^g   Hanauer, Stephen B ^h   McDonald, John W d ⁱ  

^a Epidemiology and Biostatistics   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF OTTAWA   (Canada)

^g UNIVERSITY OF ALBERTA   (Canada)

^h UNIVERSITY OF CHICAGO   (United States)

ⁱ UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; METHOTREXATE; OROSOMUCOID; PLACEBO; PREDNISONE;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROHN DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION;

ADULT; CROHN DISEASE; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; METHOTREXATE; OROSOMUCOID; REMISSION, SPONTANEOUS; TREATMENT OUTCOME;

EID: 0028899859     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199502023320503     Document Type: Article

References (38)

1. Summers RW, Switz DM, Sessions JT Jr, National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979; 77: 847-869
2. Malchow H, Ewe K, Brandes JW, European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984; 86: 249-266
3. Binder V, Hendriksen C, Kreiner S Prognosis in Crohn's disease - based on results from a regional patient group from the county of Copenhagen. Gut 1985; 26: 146-150
4. Lukert BP, Raisz LG Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990; 112: 352-364
5. Adachi JD, Bensen WG, Hodsman AB Corticosteroid-induced osteoporosis. Semin Arthritis Rheum 1993; 22: 375-384
6. Caldwell JR, Furst DE The efficacy and safety of low-dose corticosteroids for rheumatoid arthritis. Semin Arthritis Rheum 1991; 21: 1-11
7. Tripathi RC, Kirschner BS, Kipp M, Corticosteroid treatment for inflammatory bowel disease in pediatric patients increases intraocular pressure. Gastroenterology 1992; 102: 1957-1961
8. Singleton JW, Law DH, Kelly ML Jr, Mekhjian HS, Sturdevant RAL National Cooperative Crohn's Disease Study: adverse reactions to study drugs. Gastroenterology 1979; 77: 870-882
9. Sturdevant RAL, Singleton JW, Deren JJ, Law DH, McCleery JL Azathioprine-related pancreatitis in patients with Crohn's disease. Gastroenterology 1979; 77: 883-886
10. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111: 641-649
11. Brynskov J, Freund L, Rasmussen SN, A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease. N Engl J Med 1989; 321: 845-850
12. Feagan BG, McDonald JWD, Rochon JR, Low-dose cyclosporine for the treatment of Crohn's disease. N Engl J Med 1994; 330: 1846-1851
13. Jewell D, Lennard-Jones JE, Cyclosporin Study Group of Great Britain and Ireland. Oral cyclosporin for chronic active Crohn's disease: a multicentre controlled trial. Eur J Gastroenterol Hepatol 1994; 6: 499-505
14. Klippel JH, Decker JL Methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312: 853-854
15. Weinblatt ME, Coblyn JS, Fox DA, Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312: 818-822
16. Black RL, O'Brien WM, Van Scott EJ, Auerbach R, Eisen AZ, Bunim JJ Methotrexate therapy in psoriatic arthritis: double-blind study on 21 patients. JAMA 1964; 189: 743-747
17. Willkens RF, Williams HJ, Ward JR, Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984; 27: 376-381
18. Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR Methotrexate induces clinical and histological remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989; 110: 353-356
19. Lewis JH, Schiff E, Brooks WS Methotrexate-induced chronic liver injury: guidelines for detection and prevention. Am J Gastroenterol 1988; 83: 1337-1345
20. Best WR, Becktel JM, Singleton JW Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology 1979; 77: 843-846
21. Best WR, Becktel JM, Singleton JW, Kern F Jr Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-444
22. Guyatt G, Mitchell A, Irvine EJ, A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989; 96: 804-810
23. Irvine EJ, Feagan B, Rochon J, Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Gastroenterology 1994; 106: 287-296
24. Wright JP, Alp MN, Young GO, Tigler-Wybrandi N Predictors of acute relapse of Crohn's disease: a laboratory and clinical study. Dig Dis Sci 1987; 32: 164-170
25. Alpha1-Acid Glycoprotein (AAG) Assay. Galway, Ireland: Beckman Scientific Instruments, 1991 (package insert).
26. SAS Institute Inc. SAS procedures guide. Version 6. 3rd ed. Cary, N.C.: SAS Institute, 1990.
27. Jennrich RI, Schluchter MD Unbalanced repeated-measures models with structured covariance matrices. Biometrics 1986; 42: 805-820
28. McCullagh P, Nelder JA. Generalized linear models. 2nd ed. London: Chapman and Hall, 1989.
29. Johansson BA Visual field defects during low-dose methotrexate therapy. Doc Ophthalmol 1992; 79: 91-94
30. Brick JE, Moreland LW, Al-Kawas F, Chang WWL, Layne RD, DiBartolomeo AG Prospective analysis of liver biopsies before and after methotrexate therapy in rheumatoid patients. Semin Arthritis Rheum 1989; 19: 31-44
31. Kremer JM, Alarcon GS, Lightfoot RW Jr, Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994; 37: 316-328
32. Whiting-O'Keefe QE, Fye KH, Sack KD Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991; 90: 711-716
33. Searles G, McKendry RJ Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors: four case reports and a review of the literature. J Rheumatol 1987; 14: 1164-1171
34. al-Awadhi A, Dale P, McKendry RJR Pancytopenia associated with low dose methotrexate therapy: a regional survey. J Rheumatol 1993; 20: 1121-1125
35. Kozlowski RD, Steinbrunner JV, MacKenzie AH, Clough JD, Wilke WS, Segal AM Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. Am J Med 1990; 88: 589-592
36. Sachar DB Budesonide for inflammatory bowel disease: is it a magic bullet? N Engl J Med 1994; 331: 873-874
37. Greenberg GR, Feagan BG, Martin F, Oral budesonide for active Crohn's disease. N Engl J Med 1994; 331: 836-841
38. Singleton JW, Hanauer SB, Gitnick GL, Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Gastroenterology 1993; 104: 1293-1301